ECSP17021897A - Compuestos y composiciones como inhibidores de quinasa raf - Google Patents
Compuestos y composiciones como inhibidores de quinasa rafInfo
- Publication number
- ECSP17021897A ECSP17021897A ECIEPI201721897A ECPI201721897A ECSP17021897A EC SP17021897 A ECSP17021897 A EC SP17021897A EC IEPI201721897 A ECIEPI201721897 A EC IEPI201721897A EC PI201721897 A ECPI201721897 A EC PI201721897A EC SP17021897 A ECSP17021897 A EC SP17021897A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- compositions
- raf kinase
- kinase inhibitors
- salts
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000009929 raf Kinases Human genes 0.000 title abstract 2
- 108010077182 raf Kinases Proteins 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
RESUMEN La presente invención proporciona un compuesto de Fórmula I: donde X, Y, Z, R1 y R2 son como se describen en el presente documento, y sales de los mismos y usos terapéuticos de estos compuestos para el tratamiento de trastornos asociados con la actividad de la quinasa RAF. La invención proporciona además composiciones farmacéuticas que comprenden estos compuestos, y composiciones que comprenden estos compuestos y un co-agente terapéutico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462049469P | 2014-09-12 | 2014-09-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP17021897A true ECSP17021897A (es) | 2018-02-28 |
Family
ID=54148595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECIEPI201721897A ECSP17021897A (es) | 2014-09-12 | 2017-04-07 | Compuestos y composiciones como inhibidores de quinasa raf |
Country Status (30)
Country | Link |
---|---|
US (2) | US9573969B2 (es) |
EP (1) | EP3191472B1 (es) |
JP (1) | JP6678655B2 (es) |
KR (1) | KR20170053686A (es) |
CN (1) | CN107108671B (es) |
AP (1) | AP2017009830A0 (es) |
AR (1) | AR101815A1 (es) |
AU (1) | AU2015313782B2 (es) |
BR (1) | BR112017004741A2 (es) |
CA (1) | CA2960971A1 (es) |
CL (1) | CL2017000541A1 (es) |
CO (1) | CO2017002292A2 (es) |
CR (1) | CR20170092A (es) |
CU (1) | CU20170026A7 (es) |
DO (1) | DOP2017000066A (es) |
EA (1) | EA031061B1 (es) |
EC (1) | ECSP17021897A (es) |
ES (1) | ES2729243T3 (es) |
IL (1) | IL250950A0 (es) |
MX (1) | MX2017003233A (es) |
NI (1) | NI201700029A (es) |
PE (1) | PE20171338A1 (es) |
PH (1) | PH12017500416A1 (es) |
SG (1) | SG11201701734QA (es) |
SV (1) | SV2017005405A (es) |
TN (1) | TN2017000075A1 (es) |
TW (1) | TWI603977B (es) |
UY (1) | UY36294A (es) |
WO (1) | WO2016038581A1 (es) |
ZA (1) | ZA201701633B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE053431T2 (hu) | 2013-03-14 | 2021-07-28 | Boehringer Ingelheim Int | Szubsztituált 2-aza-biciklo[2.2.1]heptán-3-karbonsav-(benzil-ciano-metil)-amidok, mint a katepszin-C inhibitorai |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
BR112016016289B1 (pt) * | 2014-01-14 | 2023-02-07 | Takeda Pharmaceutical Company Limited | Heteroaris e usos dos mesmos |
UY36294A (es) * | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
UA118610C2 (uk) | 2014-09-12 | 2019-02-11 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Спіроциклічні інгібітори катепсину c |
CN109715163B (zh) * | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | 包含raf抑制剂和erk抑制剂的治疗组合 |
CA3069564A1 (en) * | 2017-08-03 | 2019-02-07 | Novartis Ag | Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor |
US20230081390A1 (en) * | 2019-03-22 | 2023-03-16 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
WO2020227020A1 (en) | 2019-05-03 | 2020-11-12 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
AU2020371727A1 (en) | 2019-10-24 | 2022-05-26 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
US11407737B2 (en) | 2020-09-18 | 2022-08-09 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
WO2022066580A1 (en) * | 2020-09-23 | 2022-03-31 | Kinnate Biopharma Inc. | Raf degrading compounds |
US11377431B2 (en) | 2020-10-12 | 2022-07-05 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
CN117561057A (zh) | 2021-04-23 | 2024-02-13 | 金耐特生物制药公司 | 用raf抑制剂治疗癌症 |
CA3216258A1 (en) * | 2021-04-23 | 2022-10-27 | Stephen W. Kaldor | Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof |
CN117337292A (zh) * | 2021-05-12 | 2024-01-02 | 勃林格殷格翰国际有限公司 | 作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物 |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3707475A (en) | 1970-11-16 | 1972-12-26 | Pfizer | Antiinflammatory imidazoles |
DE3029376A1 (de) | 1980-07-31 | 1982-03-18 | Nepera Chemical Co. Inc., Harriman, N.Y. | Verfahren zur herstellung von 2,4,5-tris-pyridylimidazolen |
DE3486009T2 (de) | 1983-09-09 | 1993-04-15 | Takeda Chemical Industries Ltd | 5-pyridyl-1,3-thiazol-derivate, ihre herstellung und anwendung. |
JP2722586B2 (ja) | 1989-01-13 | 1998-03-04 | 大正製薬株式会社 | インドリルイミダゾール誘導体 |
JP2808460B2 (ja) | 1989-11-16 | 1998-10-08 | 大正製薬株式会社 | イミダゾール誘導体 |
US6358932B1 (en) | 1994-05-31 | 2002-03-19 | Isis Pharmaceticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
GB2306108A (en) | 1995-10-13 | 1997-04-30 | Merck & Co Inc | Treatment of Raf-mediated cancers with imidazole derivatives |
US6268308B1 (en) | 1996-08-27 | 2001-07-31 | Syngenta Crop Protection, Inc. | Herbicidal S-substituted 1,2,4,6-thiatriazines |
US6248771B1 (en) | 1997-03-05 | 2001-06-19 | Sugen, Inc. | Formulations for hydrophobic pharmaceutical agents |
AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
GB9711650D0 (en) | 1997-06-05 | 1997-07-30 | Pfizer Ltd | Compounds useful in therapy |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
US6211177B1 (en) | 1998-11-24 | 2001-04-03 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives |
EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
US6465493B1 (en) | 1999-04-09 | 2002-10-15 | Smithkline Beecham Corporation | Triarylimidazoles |
MXPA01010292A (es) | 1999-04-15 | 2002-10-23 | Squibb Bristol Myers Co | Inhibidores ciclicos de la proteina tirosina cinasa. |
JP2000302680A (ja) | 1999-04-23 | 2000-10-31 | Takeda Chem Ind Ltd | 脳保護剤 |
US6310574B1 (en) | 1999-08-05 | 2001-10-30 | Vega Grieshaber Kg | Level transmitter |
ATE339406T1 (de) | 1999-09-23 | 2006-10-15 | Astrazeneca Ab | Chinazoline verbindungen als heilmittel |
PL355912A1 (en) | 1999-11-22 | 2004-05-31 | Smithkline Beecham Plc. | Novel compounds |
AU2001232809A1 (en) | 2000-01-18 | 2001-07-31 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
JP2003520233A (ja) | 2000-01-18 | 2003-07-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | ジャイレースインヒビターおよびそれらの使用 |
AR029803A1 (es) | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
ATE266022T1 (de) | 2000-03-06 | 2004-05-15 | Smithkline Beecham Plc | Imidazol derivate als raf kinase inhibitoren |
GB0005357D0 (en) | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
WO2001074811A2 (en) | 2000-03-30 | 2001-10-11 | Takeda Chemical Industries, Ltd. | Substituted 1,3-thiazole compounds, their production and use |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
IL152848A0 (en) | 2000-06-12 | 2003-06-24 | Eisai Co Ltd | 1,2-dihydropyridine derivatives, pharmaceutical compositions containing the same and methods for the production thereof |
HUP0400651A2 (hu) | 2000-11-07 | 2004-06-28 | Bristol-Myers Squibb Company | Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények |
EP1343779B1 (en) | 2000-11-20 | 2007-06-27 | Smithkline Beecham Corporation | Novel compounds |
EP1341771A2 (en) | 2000-11-29 | 2003-09-10 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
DE60215139T2 (de) | 2001-01-26 | 2007-08-16 | Chugai Seiyaku K.K. | Malonyl coa-decarboxylase inhibitoren als stoffwechselmodulatoren |
CA2437248A1 (en) | 2001-02-02 | 2002-08-15 | Takeda Chemical Industries, Ltd. | Jnk inhibitor |
WO2002076960A1 (en) | 2001-03-22 | 2002-10-03 | Abbott Gmbh & Co. Kg | Transition metal mediated process |
JP2002338537A (ja) | 2001-05-16 | 2002-11-27 | Mitsubishi Pharma Corp | アミド化合物およびその医薬用途 |
GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
US7071216B2 (en) | 2002-03-29 | 2006-07-04 | Chiron Corporation | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase |
US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
CN1681810A (zh) | 2002-09-18 | 2005-10-12 | 辉瑞产品公司 | 作为转化生长因子(tgf)抑制剂的新的噁唑和噻唑化合物 |
OA12928A (en) | 2002-09-18 | 2006-10-13 | Pfizer Prod Inc | Novel imidazole compounds as transforming growth factor (TGF) inhibitors. |
CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
US7531553B2 (en) | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
CA2542105C (en) | 2003-10-08 | 2011-08-02 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
US7423150B2 (en) | 2003-10-16 | 2008-09-09 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of Raf kinase |
DK1692113T3 (en) | 2003-11-14 | 2018-01-08 | Lorus Therapeutics Inc | ARYLIMIDAZOLES AND USE THEREOF AS ANTICANCES |
MY146532A (en) | 2004-03-05 | 2012-08-15 | Taisho Pharmaceutical Co Ltd | Thiazole derivative |
KR100749566B1 (ko) | 2004-04-21 | 2007-08-16 | 이화여자대학교 산학협력단 | Alk5 및/또는 alk4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체 |
WO2005105814A1 (en) | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
PE20060315A1 (es) | 2004-05-24 | 2006-05-15 | Irm Llc | Compuestos de tiazol como moduladores de ppar |
US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
GB0415365D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415367D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
WO2006026306A1 (en) | 2004-08-31 | 2006-03-09 | Biogen Idec Ma Inc. | Pyrimidinylimidazoles as tgf-beta inhibitors |
WO2006038734A1 (en) | 2004-10-08 | 2006-04-13 | Astellas Pharma Inc. | Pyridazinone derivatives cytokines inhibitors |
AU2005295734A1 (en) | 2004-10-15 | 2006-04-27 | Biogen Idec Ma Inc. | Methods of treating vascular injuries |
JP2007246520A (ja) | 2006-02-15 | 2007-09-27 | Takeda Yuichiro | Rage阻害剤 |
EP2007393B1 (en) | 2006-04-07 | 2013-08-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers |
WO2008071605A2 (en) | 2006-12-15 | 2008-06-19 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
ES2525716T3 (es) | 2007-06-27 | 2014-12-29 | Astrazeneca Ab | Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares |
TWI444379B (zh) | 2007-06-29 | 2014-07-11 | Sunesis Pharmaceuticals Inc | 有用於作為Raf激酶抑制劑之化合物 |
EP2167497A2 (en) | 2007-06-29 | 2010-03-31 | Sunesis Pharmaceuticals, Inc. | Heterocyclic compounds useful as raf kinase inhibitors |
EP2176249A2 (en) | 2007-07-02 | 2010-04-21 | Boehringer Ingelheim International GmbH | New chemical compounds |
US20100261723A1 (en) | 2007-07-09 | 2010-10-14 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
BRPI0814423B1 (pt) | 2007-07-17 | 2022-04-19 | Plexxikon, Inc | Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos |
AU2008279776B2 (en) | 2007-07-19 | 2013-05-23 | Merck Sharp & Dohme Corp. | Heterocyclic amide compounds as protein kinase inhibitors |
US20110190280A1 (en) | 2007-08-29 | 2011-08-04 | George Adjabeng | Thiazole And Oxazole Kinase Inhibitors |
WO2009030952A2 (en) | 2007-09-05 | 2009-03-12 | Astrazeneca Ab | Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway |
WO2009047163A1 (en) | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
TW200940537A (en) | 2008-02-26 | 2009-10-01 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
KR101408517B1 (ko) | 2008-03-21 | 2014-06-17 | 노파르티스 아게 | 신규한 헤테로시클릭 화합물 및 그의 용도 |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
JP2011524365A (ja) | 2008-06-11 | 2011-09-01 | アイアールエム・リミテッド・ライアビリティ・カンパニー | マラリアの処置に有用な化合物および組成物 |
CN102105459B (zh) | 2008-07-24 | 2014-09-10 | 内尔维阿诺医学科学有限公司 | 作为蛋白激酶抑制剂的3,4-二芳基吡唑类 |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
CA3013000C (en) | 2008-12-19 | 2022-12-13 | Vertex Pharmaceuticals Incorporated | Pyrazine derivatives useful as inhibitors of atr kinase |
AU2009334997A1 (en) * | 2008-12-30 | 2011-08-04 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as Raf kinase inhibitors |
WO2011025968A1 (en) * | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | 1h-pyrazolo [ 3, 4-b] pyridine compounds for inhibiting raf kinase |
US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
AU2010291206A1 (en) | 2009-09-04 | 2012-02-23 | Novartis Ag | Bipyridines useful for the treatment of proliferative diseases |
EP2498608A4 (en) | 2009-11-10 | 2013-04-24 | Glaxosmithkline Llc | BENZOLSULFONAMIDE THIAZOL AND OXAZOLE COMPOUNDS |
US9315491B2 (en) | 2009-12-28 | 2016-04-19 | Development Center For Biotechnology | Pyrimidine compounds as mTOR and PI3K inhibitors |
KR101778320B1 (ko) | 2009-12-28 | 2017-09-13 | 잇반샤단호우징 화루마바레프로제쿠토 시엥기코우 | 1,3,4-옥사디아졸-2-카르복사미드 화합물 |
KR20110123657A (ko) | 2010-05-07 | 2011-11-15 | 에스케이케미칼주식회사 | 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
EA201201676A1 (ru) | 2010-06-25 | 2013-06-28 | Новартис Аг | Гетероарильные соединения и композиции в качестве ингибиторов протеинкиназы |
CN101993415B (zh) | 2010-09-15 | 2013-08-14 | 北京韩美药品有限公司 | 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用 |
MA34948B1 (fr) | 2011-02-07 | 2014-03-01 | Plexxikon Inc | Composes et procedes de modulation de kinase, et leurs indications |
WO2013022766A1 (en) | 2011-08-05 | 2013-02-14 | Flynn Gary A | Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors |
SG2014014369A (en) | 2011-09-01 | 2014-09-26 | Irm Llc | Compounds and compositions as c-kit kinase inhibitors |
CN102993199A (zh) * | 2011-09-09 | 2013-03-27 | 山东轩竹医药科技有限公司 | 杂环取代的吡啶并吡咯激酶抑制剂 |
AU2012311458B2 (en) | 2011-09-21 | 2016-02-04 | Cellzome Limited | Morpholino substituted urea or carbamate derivatives as mTOR inhibitors |
EP2844655A1 (en) | 2012-05-02 | 2015-03-11 | Lupin Limited | Substituted pyridine compounds as crac modulators |
AU2013261128B2 (en) | 2012-05-15 | 2015-11-12 | Novartis Ag | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
AR091654A1 (es) | 2012-07-02 | 2015-02-18 | Biogen Idec Inc | COMPUESTOS QUE CONTIENEN BIARILO COMO AGONISTAS INVERSOS DE RECEPTORES ROR-g |
US9586948B2 (en) | 2012-10-08 | 2017-03-07 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
-
2015
- 2015-09-10 UY UY0001036294A patent/UY36294A/es not_active Application Discontinuation
- 2015-09-11 AU AU2015313782A patent/AU2015313782B2/en not_active Ceased
- 2015-09-11 CU CUP2017000026A patent/CU20170026A7/es unknown
- 2015-09-11 ES ES15766660T patent/ES2729243T3/es active Active
- 2015-09-11 CA CA2960971A patent/CA2960971A1/en not_active Abandoned
- 2015-09-11 EP EP15766660.3A patent/EP3191472B1/en active Active
- 2015-09-11 JP JP2017513759A patent/JP6678655B2/ja active Active
- 2015-09-11 BR BR112017004741A patent/BR112017004741A2/pt not_active IP Right Cessation
- 2015-09-11 AP AP2017009830A patent/AP2017009830A0/en unknown
- 2015-09-11 EA EA201790599A patent/EA031061B1/ru not_active IP Right Cessation
- 2015-09-11 SG SG11201701734QA patent/SG11201701734QA/en unknown
- 2015-09-11 US US14/851,249 patent/US9573969B2/en active Active
- 2015-09-11 TW TW104130161A patent/TWI603977B/zh not_active IP Right Cessation
- 2015-09-11 TN TN2017000075A patent/TN2017000075A1/en unknown
- 2015-09-11 CR CR20170092A patent/CR20170092A/es unknown
- 2015-09-11 CN CN201580061323.4A patent/CN107108671B/zh active Active
- 2015-09-11 KR KR1020177009468A patent/KR20170053686A/ko unknown
- 2015-09-11 AR ARP150102898A patent/AR101815A1/es unknown
- 2015-09-11 MX MX2017003233A patent/MX2017003233A/es unknown
- 2015-09-11 PE PE2017000445A patent/PE20171338A1/es not_active Application Discontinuation
- 2015-09-11 WO PCT/IB2015/056986 patent/WO2016038581A1/en active Application Filing
-
2017
- 2017-01-04 US US15/397,787 patent/US9809610B2/en active Active
- 2017-03-05 IL IL250950A patent/IL250950A0/en unknown
- 2017-03-06 PH PH12017500416A patent/PH12017500416A1/en unknown
- 2017-03-07 CL CL2017000541A patent/CL2017000541A1/es unknown
- 2017-03-07 ZA ZA2017/01633A patent/ZA201701633B/en unknown
- 2017-03-08 CO CONC2017/0002292A patent/CO2017002292A2/es unknown
- 2017-03-09 DO DO2017000066A patent/DOP2017000066A/es unknown
- 2017-03-10 SV SV2017005405A patent/SV2017005405A/es unknown
- 2017-03-10 NI NI201700029A patent/NI201700029A/es unknown
- 2017-04-07 EC ECIEPI201721897A patent/ECSP17021897A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP17021897A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
NI201500120A (es) | Compuestos de biaril - amida como inhibidores de cinasa | |
CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
DOP2016000085A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
CO2017011851A2 (es) | Compuestos novedosos | |
CR20180516A (es) | Compuestos de iprrolotriazina como inhibidores de tam | |
CR20170384A (es) | Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos | |
NI201600058A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
CU20160188A7 (es) | Compuestos de indazole substituidos como inhibidores de irak4 | |
CR20150633A (es) | Derivados del bipirazol como inhibidores jak | |
NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
UY35663A (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
UY35617A (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
CL2019000476A1 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2. | |
CL2017000827A1 (es) | Inhibidores de aldosterona sintasa | |
CL2017000040A1 (es) | Inhibidores de aldosterona sintasa. | |
DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
EA201891439A1 (ru) | Трициклические соединения и их композиции в качестве ингибиторов киназ | |
CR20160175A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
UY35672A (es) | Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos |